Details for Patent: 12,023,325

Which drugs does patent 12,023,325 protect, and when does it expire?

Patent 12,023,325 protects QINLOCK and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Recent additions to Drugs Protected by US Patent 12,023,325

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Deciphera Pharms	QINLOCK	ripretinib	TABLET	213973	May 15, 2020	RX	Yes						U-3960	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED IMATINIB

Drugs Protected by US Patent 12,023,325

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes						TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED IMATINIB

International Family Members for US Patent 12,023,325

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122301
Australia	2020328538
Australia	2020329956